Abstract
Fujifilm will invest $37 million to expand its biomanufacturing business in the U.S. and the U.K. In the U.S., Fujifilm Diosynth Biotechnologies will spend $28 million on mammalian cell bioreactors at a recently opened facility in College Station, Texas. Construction of the $92 million plant was partly financed by the U.S. Biomedical Advanced Research & Development Authority. In Billingham, England, Fujifilm Diosynth will spend $9 million to expand process development capabilities. Fujifilm acquired the Texas facility in 2014 and the Billingham plant in 2011.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
